Bilateral Posterior Subthalamic Area Deep Brain Stimulation for Essential Tremor: A Case Series
Deep brain stimulation (DBS) of the posterior subthalamic area (PSA) provides a potentially effective treatment for medication-refractory essential tremor (ET). To study the clinical benefits and adverse-event profile of bilateral PSA-DBS for refractory ET. Seven patients with refractory ET underwen...
Gespeichert in:
Veröffentlicht in: | Frontiers in human neuroscience 2020-02, Vol.14, p.16-16 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Deep brain stimulation (DBS) of the posterior subthalamic area (PSA) provides a potentially effective treatment for medication-refractory essential tremor (ET).
To study the clinical benefits and adverse-event profile of bilateral PSA-DBS for refractory ET.
Seven patients with refractory ET underwent bilateral PSA-DBS surgery under general anesthesia between September 2017 and May 2018. Clinical outcome assessments, using the Essential Tremor Rating Scale, were performed at 1-, 6-, and 12-month follow-up, except for the last assessment of one patient who was followed up to 9 months. Analysis was focused on changes in patients' motor symptoms and quality of life following surgery as well as documenting the adverse-event profile associated with the surgical PSA-DBS treatment.
After surgery, patients' motor symptoms, including upper limb tremor and head tremor, were improved by 84.2% and their quality of life by 81.25% at 1-month follow-up. The clinical benefits to patients were maintained at 6-month and last follow-up. Adverse side effects included dysarthria (
= 4), balance disorder (
= 2), and paresthesia of the right limb (
= 1). No habituation effects were observed throughout the follow-up.
Bilateral PSA-DBS seems to offer an effective and safe alternative treatment for medically intractable ET, warranting further research into its clinical utility, adverse-event profile, and comparative effectiveness. |
---|---|
ISSN: | 1662-5161 1662-5161 |
DOI: | 10.3389/fnhum.2020.00016 |